MedTech Dive April 17, 2024
Elise Reuter

CEO Robert Ford highlighted new and upcoming products throughout the earnings call, calling the recently approved Triclip valve a “billion-dollar opportunity.”

Abbott CEO Robert Ford said Wednesday on an earnings call that a slate of recent approvals and a “highly productive” pipeline will accelerate growth.

The company recently received FDA authorization for a minimally invasive treatment for tricuspid regurgitation, a blood test to detect traumatic brain injury, and the ability to integrate its Freestyle Libre 2 Plus glucose sensor with Insulet’s Omnipod 5 insulin pump.

Abbott is looking to enter the competitive pulsed field ablation market with its Volt system. The company also plans to add new devices to its diabetes segment, including a dual-analyte sensor that can...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Medical Devices
FDA considers 2nd blood test for colon cancer — but advisers note concerns
Intertronics acquires Dyne Testing
NICE, NHS England unveil new pathway for medtech
UK regulator proposes recognizing overseas medical device approvals
GE HealthCare tops FDA list for AI-enabled medical device authorizations (again)

Share This Article